Free Trial
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$261.34
-0.6%		$257.87
$190.75
▼
$269.39
$461.42B0.246.41 million shs440,695 shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$143.24
-1.0%		$143.63
$112.41
▼
$157.29
$177.68B0.316.84 million shs500,647 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%-0.45%+2.73%+3.34%+12.48%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.00%-4.10%-4.14%+11.67%+28.44%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$261.34
-0.6%		$257.87
$190.75
▼
$269.39
$461.42B0.246.41 million shs440,695 shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$143.24
-1.0%		$143.63
$112.41
▼
$157.29
$177.68B0.316.84 million shs500,647 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
0.00%-0.45%+2.73%+3.34%+12.48%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.00%-4.10%-4.14%+11.67%+28.44%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.87
Moderate Buy$272.393.47% Upside
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.79
Moderate Buy$158.789.70% Upside

Current Analyst Ratings Breakdown

Latest GILD and ABBV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/29/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
9/16/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$250.00 ➝ $240.00
9/14/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
9/10/2026
AbbVie Inc. stock logo
ABBV
AbbVie
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$300.00 ➝ $315.00
9/10/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$155.00 ➝ $175.00
9/8/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/8/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price Target$276.00 ➝ $282.00
8/31/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/20/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$298.00 ➝ $303.00
8/17/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$295.00 ➝ $300.00
8/13/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$235.00 ➝ $300.00
(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$61.16B7.61$15.17 per share17.35($1.83) per share-143.86
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$29.44B6.10$10.47 per share13.82$18.23 per share7.94
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.23B$3.5474.3716.331.199.80%-422.07%14.34%10/30/2026 (Estimated)
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$8.51B-$2.67N/A14.66N/A-10.64%-2.11%-0.75%10/29/2026 (Estimated)

Latest GILD and ABBV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/30/2026Q3 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$3.86N/AN/AN/A$17.31 billionN/A
10/29/2026Q3 2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$2.12N/AN/AN/A$7.77 billionN/A
8/3/2026Q2 2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-$7.25-$6.75+$0.50-$8.45$7.40 billion$7.80 billion
7/31/2026Q2 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$3.61$3.65+$0.04$2.03$16.80 billion$16.99 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.922.63%+6.80%195.48%53 Years
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.282.27%+3.04%N/A 10 Years

Latest GILD and ABBV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/10/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.732.71%10/15/202610/15/202611/16/2026
7/28/2026
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.822.24%9/15/20269/15/20269/29/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
N/A
0.81
0.69
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.03
1.27
1.09

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.06%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
57,0001.77 billion1.77 billionOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,0001.24 billion1.24 billionOptionable

Recent News About These Companies

Nurix Extends Gilead Oncology Research Collaboration For Two Years
 |  rttnews.comhttps://www.rttnews.com/3696503/nurix-extends-gilead-oncology-research-collaboration-for-two-years.aspx
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
 |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/nurix-therapeutics-announces-second-research-110000618.html
Zacks Research Lowers Earnings Estimates for Gilead Sciences
October 5 at 1:26 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-zacks-research-lowers-earnings-estimates-for-gilead-sciences-2026-10-05/
Gilead (NASDAQ: GILD) CEO sells 15,000 shares under a preset plan
October 4 at 12:00 PM  |  defenseworld.netD
Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O'day Sells 15,000 Shares of Stock
October 3 at 5:23 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082807
Insider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Company Stock
October 3 at 5:22 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-gild-insider-buying-and-selling-2026-10-03/
Contrasting Gilead Sciences (NASDAQ:GILD) and BridgeBio Pharma (NASDAQ:BBIO)
October 3 at 4:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082467
31,384 Gilead Sciences, Inc. $GILD Shares Sold by CX Institutional
October 3 at 3:07 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-31384-gilead-sciences-inc-gild-shares-sold-by-cx-institutional-2026-10-03/
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
October 2 at 6:50 PM  |  zacks.comhttps://www.zacks.com/stock/news/2999681/gilead-sciences-gild-stock-sinks-as-market-gains-what-you-should-know?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_6v1-2999681
Insider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Stock
October 2 at 5:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-gilead-sciences-nasdaq-gild-ceo-sells-15000-shares-of-stock-2026-10-02/
Biktarvy Drives Gilead Sciences (GILD) Revenue to $7.8 Billion in Latest Quarter
October 2 at 12:32 PM  |  blockonomi.comhttps://blockonomi.com/biktarvy-drives-gilead-sciences-gild-revenue-to-7-8-billion-in-latest-quarter/
Gilead Sciences (GILD) Stock Up 35% as HIV Drugs Fuel Growth Streak
October 2 at 12:32 PM  |  coincentral.comC
More Upside Awaits for Gilead Sciences Stock. Stay Invested.
October 2 at 1:36 AM  |  finance.yahoo.comhttps://finance.yahoo.com/m/681b7c5e-869b-3392-9263-15a8e8eae447/more-upside-awaits-for-gilead.html
More Upside Awaits for Gilead Sciences Stock. Stay Invested.
October 1, 2026  |  barrons.comhttps://www.barrons.com/articles/gilead-sciences-stock-stay-invested-more-upside-awaits-e1c38c22
Confluence Investment Management LLC Cuts Position in Gilead Sciences, Inc. $GILD
October 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-confluence-investment-management-llc-cuts-position-in-gilead-sciences-inc-gild-2026-10-01/
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
October 1, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2998730/gilead-sciences-inc-gild-is-a-trending-stock-facts-to-know-before-betting-on-it?cid=cs-stocknewsapi-ft-fundamental_analysis|most_searched_stocks_v1-2998730
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
October 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/gilead-sciences-inc-gild-trending-120005017.html
Gilead Sciences (NASDAQ:GILD) Stock Rating Cut to "Hold" at Zacks Research
October 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-gilead-sciences-nasdaq-gild-stock-rating-cut-to-hold-at-zacks-research-2026-10-01/
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors
September 30, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/gilead-sciences-gild-declines-more-210004893.html
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors
September 30, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2998538/gilead-sciences-gild-declines-more-than-market-some-information-for-investors?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_6v2-2998538
Former Gilead CIO and CSL Chief Digital & Information Officer Mark Hill Joins Sware Board of Directors
September 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/former-gilead-cio-csl-chief-130000956.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

AbbVie stock logo

AbbVie NYSE:ABBV

$261.34 -1.48 (-0.56%)
As of 10:41 AM Eastern
This is a fair market value price provided by Massive. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$143.24 -1.50 (-1.03%)
As of 10:41 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas